Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson for Moderate to Severe COVID-19
NCT04606069Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regadenoson in coronavirus disease 2019 (COVID-19), sponsored by University of Maryland, Baltimore. Started May 2021; status: completed.
02
Drugs
regadenoson
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04606069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606069.